ClinicalTrials.gg
CompletedNCT01619085Updated Mar 25, 2022Results posted

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of Nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 173 sites in 24 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
752
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
Largest of 16
752 · median 49
Started
2012
the only one that year
Phase 3
2 of 16
none open now
Registered
2nd of 16
by date
Lead sponsor
6 of 16
Boehringer Ingelheim

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one has the largest enrollment, is the only one that started in 2012, is one of 2 in phase 3, and was the 2nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed consistent with International Conference on Harmonisation-Good Clinical Practices (ICH-GCP) and local laws prior to trial participation.
  2. Patients from trials 1199.32 or 1199.34 who completed the 52 weeks treatment period and performed the follow-up visit.

Exclusion criteria

Exclusion criteria:

  1. (AST), Alanine aminotransferase (ALT) > 1.5 fold (ULN) (Patients who completed the parent trial with transaminase values > 1.5 fold ULN but \< 3 fold ULN are considered eligible)
  2. > 1.5 fold ULN
  3. Bleeding risk
  4. Planned major surgery within the next 3 months, including lung transplantation, major abdominal or major intestinal surgery.
  5. New major thrombo-embolic events developed after completion of the parent trial.
  6. Time period > 12 weeks between Visit 9 of the parent trial and Visit 2 of this study.
  7. Usage of any drug after completion of the parent trial or planned usage of a specific investigational drug during the course of this trial.
  8. A disease or condition which in the opinion of investigator may put the patient at risk because of participation in this trial or limit the patients' ability to participate in this trial.
  9. Alcohol or drug abuse which in the opinion of the investigator would interfere with trial participation.
  10. Pregnant women or women who are breast feeding or of child bearing potential not using two effective methods of (one barrier and one highly effective non-barrier) for at least 1 month prior to Visit 2 and/or not committing to using it until 3 months after end of treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
752 participants (actual)

Study arms

  • Experimental
    All subjects

    patient to receive a capsule containing Nintedanib twice a day

    Drug: Nintedanib

Interventions

  • Nintedanib twice a day

    Also known as: BIBF 1120

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    This is the measure for percentage of patients with adverse events (AEs) observed during the trial. The incidence of adverse events (% of patients) over the course of the trial, including the incidence of serious AEs, AEs leading to discontinuation, and fatal AEs are presented.

    Time frame: From first drug administration until end of treatment period + 28 days, in total up to 56.3 months plus 28 days.

07

Results

Posted Jul 26, 2018

Participant flow

This was a prospective, open-label extension trial in which patients with Idiopathic pulmonary fibrosis (IPF), who had completed 52 weeks of treatment and the follow-up period in the randomised, double-blind, placebo-controlled parent trials 1199.32(NCT01335464)/.34(NCT01335477) and who needed access to nintedanib outside of the discontinued parent trials 1199.35(NCT01170065)/.187(NCT01979952).

Participant flow — Overall Study
MilestoneTotal (1199.32/.34/.35/.187)
Started752
Treated751
Completed227
Not completed525
Withdrew: Adverse event231
Withdrew: Protocol violation4
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject45
Withdrew: Other than specified96
Withdrew: Not treated1
Withdrew: Death145

Outcome measures

PrimaryIncidence of Adverse Events (AEs)

This is the measure for percentage of patients with adverse events (AEs) observed during the trial. The incidence of adverse events (% of patients) over the course of the trial, including the incidence of serious AEs, AEs leading to discontinuation, and fatal AEs are presented.

Time frame:
From first drug administration until end of treatment period + 28 days, in total up to 56.3 months plus 28 days.
Reported as:
Number · Percentage of patients (%)
Incidence of Adverse Events (AEs)
Percentage of patients (%)Total (1199.32/.34)
Any AEs98.5
AEs leading to discontinuation of trial drug42.6
Serious AEs68.9
Fatal AEs23.8

Adverse events

Collected over From first drug administration in this study until 28 days after the last drug, up to 7.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total (1199.32/.34)182/734 (24.8%)509/734 (69.3%)671/734 (91.4%)
Placebo (1199.32/.34)78/304 (25.7%)208/304 (68.4%)281/304 (92.4%)
Nintedanib 150 Bid (1199.32/.34)104/430 (24.2%)301/430 (70%)390/430 (90.7%)
Placebo (1199.187)0/7 (0%)0/7 (0%)3/7 (42.9%)
Nintedanib 100 Bid (1199.35)0/2 (0%)0/2 (0%)1/2 (50%)
Nintedanib 150 Bid (1199.35/.187)0/8 (0%)1/8 (12.5%)2/8 (25%)
Total (1199.35/.187)0/17 (0%)1/17 (5.9%)6/17 (35.3%)
Total (1199.32/.34/.35/.187)182/751 (24.2%)510/751 (67.9%)677/751 (90.1%)
Most frequent serious events
Showing 10 of 364
Most frequent serious events
EventTotal (1199.32/.34)Placebo (1199.32/.34)Nintedanib 150 Bid (1199.32/.34)Placebo (1199.187)Nintedanib 100 Bid (1199.35)Nintedanib 150 Bid (1199.35/.187)Total (1199.35/.187)Total (1199.32/.34/.35/.187)
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders153/73464/30489/4300/70/20/80/17153/751
PneumoniaInfections and infestations99/73440/30459/4300/70/20/80/1799/751
CholelithiasisHepatobiliary disorders9/7344/3045/4300/70/21/81/1710/751
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders48/73422/30426/4300/70/20/80/1748/751
Respiratory failureRespiratory, thoracic and mediastinal disorders35/7349/30426/4300/70/20/80/1735/751
DyspnoeaRespiratory, thoracic and mediastinal disorders38/73416/30422/4300/70/20/80/1738/751
Pulmonary embolismRespiratory, thoracic and mediastinal disorders17/73411/3046/4300/70/20/80/1717/751
HypoxiaRespiratory, thoracic and mediastinal disorders13/7349/3044/4300/70/20/80/1713/751
Respiratory tract infectionInfections and infestations13/7348/3045/4300/70/20/80/1713/751
Acute respiratory failureRespiratory, thoracic and mediastinal disorders15/7344/30411/4300/70/20/80/1715/751
Most frequent other events
Showing 10 of 34
Most frequent other events
EventTotal (1199.32/.34)Placebo (1199.32/.34)Nintedanib 150 Bid (1199.32/.34)Placebo (1199.187)Nintedanib 100 Bid (1199.35)Nintedanib 150 Bid (1199.35/.187)Total (1199.35/.187)Total (1199.32/.34/.35/.187)
DiarrhoeaGastrointestinal disorders514/734213/304301/4302/70/20/82/17516/751
InfluenzaInfections and infestations35/73411/30424/4300/71/20/81/1736/751
CoughRespiratory, thoracic and mediastinal disorders166/73466/304100/4300/70/20/80/17166/751
NauseaGastrointestinal disorders146/73470/30476/4300/70/20/80/17146/751
BronchitisInfections and infestations145/73454/30491/4300/70/20/80/17145/751
NasopharyngitisInfections and infestations152/73462/30490/4300/70/20/80/17152/751
Weight decreasedInvestigations123/73463/30460/4300/70/20/80/17123/751
Decreased appetiteMetabolism and nutrition disorders104/73458/30446/4300/70/20/80/17104/751
Upper respiratory tract infectionInfections and infestations109/73438/30471/4300/70/20/80/17109/751
DyspnoeaRespiratory, thoracic and mediastinal disorders118/73448/30470/4300/70/21/81/17119/751

Baseline characteristics

Treated set (TS): The data set consisted of all patients who were dispensed trial medication and were documented to have taken at least one dose, and had participated in 1199.32/.34 parent trials.

Age, Continuous
Age, Continuous(Years)Total (1199.32/.34)
Mean67.2 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Total (1199.32/.34)
Female147
Male587
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total (1199.32/.34)
American Indian or Alaska Native1
Asian214
Native Hawaiian or Other Pacific Islander0
Black or African American2
White431
More than one race0
Unknown or Not Reported86
08

Study locations

173 sites
  • Jasper Summit Research, LLC
    Jasper, Alabama 35501, United States
  • Pulmonary Associates
    Phoenix, Arizona 85006, United States
  • University of California
    Los Angeles, California 90095-1690, United States
  • University of California
    San Francisco, California 94143, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • University of California
    Torrance, California 90505, United States
  • Western Connecticut Medical Group
    Danbury, Connecticut 06810, United States
  • Pulmonary Assoc of Stamford
    Stamford, Connecticut 06902, United States
  • Cleveland Clinic
    Weston, Florida 33331, United States
  • Georgia Clinical Research
    Austell, Georgia 30106, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Via Christi Clinic, PA
    Wichita, Kansas 67208, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Minnesota Lung Center
    Minneapolis, Minnesota 55407, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Pulmonary and Critical Care Associates
    Albany, New York 12205, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States
  • New York Presbyterian Hospital
    New York, New York 10032, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0565, United States
  • ID Clinical Research, LTD
    Toledo, Ohio 43608, United States
  • The Oregon Clinic
    Portland, Oregon 97220, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5735, United States
  • FDC Seifer PLC Pulmonary
    Shelbyville, Tennessee 37160, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75235-8550, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Metroplex Pul and Sleep Ctr
    McKinney, Texas 75069-1769, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Lynchburg Pulmonary Associates
    Lynchburg, Virginia 24501, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Repatriation General Hospital
    Concord, New South Wales 2137, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Alfred Hospital
    Melbourne, Victoria 3000, Australia
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 3A7, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Instituto Nacional del Tórax
    Santiago de Chile, 7500000, Chile
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Xiangya Hospital, Central South University
    Changsha, 410008, China
  • West China Hospital
    Chengdu, 610042, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330006, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • General Hospital of Shenyang Military Region
    Shenyang, 110015, China
  • Xijing Hospital
    Xi'An, 710032, China
  • General Hospital of Ningxia Medical University
    Yinchuan, 750004, China
  • Thomayer Hospital
    Prague 4, 140 59, Czechia
  • University Hospital Na Bulovce, Prague
    Prague 8, 180 81, Czechia
  • Masaryk Hospital, Usti nad Labem
    Usti nad Labem, 401 13, Czechia
  • HYKS Keuhkosairauksien tutkimusyksikkö
    Helsinki, 00029, Finland
  • Mehiläinen Kielotie, Vantaa
    Vantaa, 01300, Finland
  • HOP Avicenne
    Bobigny, 93009, France
  • HOP Bocage
    Dijon, 21079, France
  • HOP Calmette
    Lille Cedex, 59037, France
  • HOP Louis Pradel
    Lyon cedex, 69677, France
  • HOP Nord
    Marseille, 13015, France
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • HOP Pasteur
    Nice, 06002, France
  • HOP Européen G. Pompidou
    Paris, 75015, France
  • HOP Bichat
    Paris, 75877, France
  • HOP Tenon
    Paris, 75970, France
  • HOP Maison Blanche
    Reims, 51092, France
  • HOP Pontchaillou
    Rennes Cedex 9, 35033, France
  • HOP Larrey
    Toulouse, 31059, France
  • CIMS Studienzentrum Bamberg GmbH
    Bamberg, 96049, Germany
  • Evangelische Lungenklinik Berlin
    Berlin-Buch, 13125, Germany
  • Helios Klinikum Emil von Behring
    Berlin, 14165, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Coswig, 01640, Germany
  • Klinik Donaustauf
    Donaustauf, 93093, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Universitätsklinikum Freiburg
    Freiburg/Breisgau, 79106, Germany
  • Universitätsklinikum Gießen und Marburg GmbH
    Gießen, 35392, Germany
  • Universitätsmedizin Greifswald
    Greifswald, 17475, Germany
  • Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
    Grosshansdorf, 22927, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Klinikum der Universität München - Campus Großhadern
    München, 81377, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Athens Hospital of Chest Diseases "Sotiria"
    Athens, 11527, Greece
  • University Hospital of Heraklion, University Pulmonology Cl
    Heraklion, 71100, Greece
  • General University Hospital of Larissa
    Larisa, 41110, Greece
  • Mehta Hospital & Cardiopulmonary Care Centre
    Ahmedabad, 380054, India
  • Chest & Maternity Center
    Bangalore, 560010, India
  • Asthma Bhawan
    Jaipur, 302023, India
  • National Allergy Asthma Bronchitis Institute, Kolkata
    Kolkatta, 700017, India
  • P.D. Hinduja National Hospital
    Mumbai, 400016, India

Showing the first 100 of 173 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14. PubMed 30224318 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jul 2017, 60 months.

Results were first posted in Jul 2018, 1 year after primary completion.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2012
First posted
Jun 14, 2012
StartActual
Jun 6, 2012
Primary completionActual
Jul 5, 2017
CompletionActual
Feb 1, 2021
Results first posted
Jul 26, 2018
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01619085
Responsible party
Sponsor
First posted
Jun 14, 2012
Start date
Jun 6, 2012
Primary completion
Jul 5, 2017
Completion
Feb 1, 2021
Results posted
Jul 26, 2018
Last update
Mar 25, 2022

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion